IMO, if the results that have been delivered are positive (as the Ph II was) and you have other programs progressing through clinical trials well (as they are) then the CEO's report should be upbeat. It would be strange for it not to be so. The informed shareholders have signed up to drug development programs and that is what BNO is delivering. I'm happy to wait for more announcements about the outcomes of clinical trials to see where this goes and see how much increase there is in the value of the shares I hold. GLTA
BNO Price at posting:
38.0¢ Sentiment: Buy Disclosure: Held
